Natrunix

Asset

Neutralizes interleukin-1 alpha to reduce inflammation.

Stage
Phase 2
Modality
Antibody
Target
IL1A
1
Indication
1,100
Trials
1
Developer

Indications

1

In the full profile

  • Targets and what it contains3
  • Owner and partners1
  • Trials1,100
  • Evidence for its targets3
  • Competitors12
  • Aging relevance1
  • Signals1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets